Jan 12 (Reuters) - Revvity said on Monday it expects its 2025 adjusted profit per share to exceed its forecast of $4.90 to $5, as the medical equipment maker benefits from renewed demand for contract research and diagnostics services.
The company's shares were up nearly 6% in extended trading.
Pharmaceutical companies have ramped up drug development in the U.S. amid evolving trade policies under President Donald Trump.
Revvity said it expects to report fourth-quarter revenue of around $772 million, above Wall Street estimates of $760.3 million, according to data compiled by LSEG.
It also expects annual revenue to grow 4% to $2.86 billion, above estimates of $2.84 billion.
The company will report its fourth-quarter and full year 2025 results on February 2.
(Reporting by Puyaan Singh in Bengaluru; Editing by Leroy Leo)
latest_posts
- 1
6 U.S. States for Climbing - 2Vehicle Lovers' Decision: Purchase A Reasonable Vehicle
- 3Travel Through France's Most Iconic Wine Regions By Train On An Immersive Seven-Day Journey
- 4The Solution to Innovative Peculiarity: Analyzing the Fate of Mankind
- 5Shakira's 2026 'Las Mujeres Ya No Lloran' U.S. Tour: How to get tickets, prices, dates and more
- How comfort foods trigger pleasure in our brains
- Vote In favor of Your Number one Savvy Beds
- Women take pride in Holy Week roles after a Spanish Catholic brotherhood's procession excluded them
- Vote in favor of your Favored kind of footwear
- No more attempts to free whale stranded off Germany, officials say
- How effective is the flu shot this year? New report shows promising results
- Which Film Has the Incomparable Melodic Score?
- All that You Really want to Be familiar with Dental Inserts Facilities
- Extraordinary Shows to Long distance race on a Plane
